All clinical trials on the European Union Clinical Trials Register (EUCTR) must report their results in the registry within a year of completion. This site tracks who's doing this and who isn't. Learn more »
These trials completed more than 12 months ago and should have reported results. Some have, some have not.
These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.
These trials have problematic data on the registry. Details why »
Status | Trial ID | Title | Completion date | Category |
---|---|---|---|---|
Not reported | 2005-000826-22 | 4 - weeks, double blind, parallel, randomized study: Comparison of repetitive transcranial magnetic stimulation (rTMS) and venlafaxine (Effectin ER) in the treatment of resistant depressive disorder | 2008-10-09 | due-trials |
Not reported | 2009-010625-39 | QEEG cordance and EEG connectivity changes after administration of subanesthetic ketamine doses in depressive disorder patients | 2012-02-28 | due-trials |
Not reported | 2013-000952-17 | The Role of mTOR (Mammalian Target of Rapamycin) Signaling Pathway in the Antidepressive Effect of Ketamine in Patients with Depressive Disorder. Uloha mTOR (mammalian target or rapamycin) signalni... | 2015-12-31 | due-trials |
Reported results | 2015-001639-19 | The efficacy of transcranial direct current stimulation (tDCS) in the treatment of depression and brain functional changes compared to venlafaxine. Účinnost a funkční změny mozku při léčbě deprese ... | 2019-04-24 | due-trials |
Not reported | 2018-001539-39 | Clinical and neurobiological predictors of response to ketamine: towards personalized treatment of depression Klinické a neurobiologické prediktory odpovědi na ketamin jako podklad pro personalizov... | 2022-04-14 | due-trials |
Other | 2018-004480-31 | Psilocybin versus ketamine – fast acting antidepressant strategies in treatment-resistant depression Psilocybin versus ketamin – strategie rychlé antidepresivní odpovědi u deprese rezistentní k léč... | not-yet-due | |
Other | 2020-005037-32 | Psilocybin - a strategy of rapid antidepressant response in depression comorbid with cancer, a randomized double-blind study with the possibility of entering open extension. Psilocybin – strategie ... | not-yet-due |